Question 1

What is the share price of Beta Drugs Limited today?

Accepted Answer

Beta Drugs Limited (BETA) is trading at ₹1,894.6. The price shown is the latest available from the exchange feed and updates through the trading session.

Question 2

What is BETA’s P/E ratio versus the sector?

Accepted Answer

BETA trades at a P/E of 135.0. Its industry median is shown alongside it in Key Stats, so you can see at a glance whether the stock is priced above or below the businesses it competes with. A lower P/E is not automatically cheaper — it can also reflect slower expected growth.

Question 3

What is BETA’s dividend yield?

Accepted Answer

BETA has a dividend yield of 0.00%, based on dividends declared over the last twelve months against the current price. The full dividend history is on the News & Filings tab.

Question 4

What is BETA’s 52-week high and low?

Accepted Answer

BETA has traded between ₹990.1 and ₹2,807.9 over the past year. The Trading Data block shows where the current price sits inside that band.

Question 5

What is the market capitalisation of Beta Drugs Limited?

Accepted Answer

Beta Drugs Limited has a market capitalisation of ₹2,162 crore.

Question 6

What is BETA’s return on equity?

Accepted Answer

BETA reports a return on equity of 10.3%. ROE measures profit generated per rupee of shareholder capital, and is most meaningful compared against others in Drug Manufacturers - Specialty & Generic.

Question 7

Who are BETA’s competitors?

Accepted Answer

The Peers block on this page lists other Drug Manufacturers - Specialty & Generic companies with their price, P/E and market capitalisation. The Valuation tab compares multiples against the industry median in more depth.

Question 8

What is BETA’s promoter holding?

Accepted Answer

Promoters hold 59.10% of BETA. The Ownership tab shows the full shareholding pattern — promoter, FII, DII and public — and how each has moved across recent quarters.

Question 9

Which indices include BETA?

Accepted Answer

Index membership is listed in the Context block on this page, along with the weight BETA carries in each. That weight is what determines how much passive money tracks the stock.

Question 10

Is Beta Drugs Limited a good buy?

Accepted Answer

We do not publish buy or sell calls. What this page gives you instead is the evidence: our Value & Investment Index for where the price sits against its own history, the Fundamental Strength Index for the quality of the business, an investment checklist of criteria applied to every stock, and pros and cons generated from BETA’s own numbers. The judgement is yours.

Revenue	₹225 crore
Net profit	₹14 crore
Operating margin	13%
EPS	₹14.14

BETA

BETA

Fundamental Strength Index

Profitability

Growth

Segment Results

Working Capital & Efficiency

BETA financial summary